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Abstract Objective To explore the ‘real-life’ therapy of
type 2 diabetes mellitus with oral antidiabetic drugs
(OADs). Methods From the PHARMO Record Linkage
System comprising linked drug dispensing and clinical
laboratory data from approximately 2.5 million individuals
in the Netherlands, among others, new users of OADs were
identified in the period 1999–2004. New users, aged
30 years and older, without insulin use before cohort entry
date and with at least one year follow-up were included.
We determined per initial therapy patient characteristics
and first therapy change. Results Overall 35,514 patients
were included. Metformin and sulfonylureas (SU) were the
most frequent initial therapy. Patients on thiazolidinedione
(TZD) monotherapy had lower percentages baseline
HbA1c C 7% compared to patients on metformin and SU.
The proportion of patients still on initial therapy after one
year ranged from 46% (TZDs) to around 60% (SU).
Among patients starting on monotherapy, add-on
(15–20%) and discontinuation (16–25%) of therapy
occurred most frequently. In patients starting on combi-
nation therapy, a switch occurred in 30% of the patients.
Conclusion In more than 40% of the patients a change in
initial OAD-therapy is already observed in the first year of
therapy. Maintaining patients on initial therapy remains a
challenge.
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Impact of findings on practice
• In the Netherlands, in more than 40% of the patients
with type 2 diabetes mellitus, a change in initial OAD-
therapy is already observed in the first year of therapy.
• New users of OADs may benefit from frequent
monitoring of effectiveness on initial therapy.
Introduction
The prevalence of type 2 diabetes mellitus (T2DM) is
growing tremendously. By 2030, T2DM is estimated to
affect more than 350 million people worldwide [1].
Changing lifestyle and dietary measures are usually the
first step in therapeutic and preventive management of this
disease. The second step is pharmacotherapy with an oral
antidiabetic drugs (OADs). In the early 1990s, three groups
of OADs were available, that is, biguanides (metformin),
sulphonylureas (SUs; e.g. tolbutamide) and a-glucosidase
inhibitors (e.g. acarbose). In 2000, a new group of OADs
became available: the thiazolidinediones (TZDs; e.g.
pioglitazone).
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The objective of the pharmacological treatment in
T2DM is to control glycaemic parameters in order to
minimize the risk of long-term complications [2]. In par-
ticular, it is important to manage cardiovascular risk fac-
tors, because T2DM accelerates vascular occlusion and
much of the excess mortality is due to cardiovascular
mortality [2]. Although clinical trials and hospital-based
cohort studies have established the merits of different
OAD-therapy strategies [2], only studies using ‘real life’
data include the complete range in diversity with regard to
patient characteristics and actual treatment patterns. This
also provides an opportunity to view OAD-therapy in the
light of the guidelines.
Aim of the study
The aim of the present study was to explore the ‘real life’
therapy of T2DM with OADs.
Methods
Setting
Data for this retrospective cohort study were obtained from
the PHARMO Record Linkage System (PHARMO RLS),
which includes, among other databases, the drug dispens-
ing records from community pharmacies linked on a
patient level to hospital discharge and clinical laboratory
records of approximately 2.5 million individuals in defined
areas of the Netherlands. These regions are representative
of all of the Netherlands [3]. The computerized drug-dis-
pensing histories contain data concerning the dispensing
date, the prescriber, the prescribed dosage regimen, the
dispensed quantity and the estimated legend duration of
use. All drugs are coded according to the Anatomical
Therapeutic Chemical (ATC) Classification. The hospital
records include detailed information concerning the pri-
mary and secondary discharge diagnoses, procedures, and
dates of hospital admission and discharge. All diagnoses
are coded according to the International Classification of
Diseases, 9th edition (ICD-9-CM).
The clinical laboratory records comprise all requests
issued by general practitioners and medical specialists. All
tests, processed by auto-analyzers directly linked to the
clinical laboratory computer, are routinely validated and
recorded independently of the test-results or physician.
Subjects
The source population included all new users of OAD
(ATC-code: A10B) from 1 January 1999 to 31 December
2004. Patients had a registration in the PHARMO RLS for
at least one year before the first OAD dispensing (cohort
entry date). A patient was defined new user of OAD, if
none of these drugs were dispensed for at least one year
before cohort entry date. New users, aged 30 years and
older, without insulin use before cohort entry date and at
least 1 year follow-up, were defined as eligible for inclu-
sion. Patients with T2DM as a complication of other pre-
existing conditions (e.g. Cushing’s syndrome, disease of
pancreas, pregnancy) were excluded based on hospital
admissions for relevant diagnoses before cohort entry date.
Treatment pattern
For patients starting on monotherapy with metformin, SU
or TZD or on combination therapy with metformin ? SU
or metformin ? TZD, the treatment pattern in the first year
was determined. For each patient, all OAD dispensings in
the first year after therapy onset were converted into epi-
sodes of continuous use of a specific OAD, based on
Catalan’s method [4]. The proportion of patients remaining
on initial OAD-therapy was defined as the number of days
of continuous use of the initial OAD from the cohort entry
date onwards (that is the duration of the first episode). For
patients not remaining on initial OAD-therapy, defined as
\365 days of continuous use of the initial OAD, the
first change in therapy was determined in the one-year
period after start, subdivided into add-on, switch and
discontinuation.
Statistical analyses
All data were analyzed using SAS programs organized
within SAS Enterprise Guide version 3.0 (SAS Institute
Inc., Cary, NC, USA) and conducted under UNIX using
SAS version 9.1.
Results
Patient characteristics
The source population included 46,183 new OAD users. Of
these, 35,514 fulfilled the inclusion criteria and were
included in the study cohort. Table 1 shows their general
characteristics.
The most frequently used initial OAD-therapies were
metformin (14,277) and SU (18,876). TZD monotherapy
was used by 310 patients. Patients starting on TZD
monotherapy were more often male (51%) and younger
and were more frequently treated by an internist (28%).
Three-quarters of new OAD users whose initial therapy
was metformin, SU or metformin ? SU, had HbA1c C 7%
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at start of initial therapy. Patients with HbA1c measure-
ments were representative for the entire cohort.
First treatment change
Table 2 shows the first change in therapy within one year
after start per type of initial OAD-therapy.
The proportion of patients still on initial therapy after
one year ranged from 46% (TZDs) to around 60% (SU).
Among those who started on monotherapy, add-on (15–
20%) and discontinuation (16–25%) of therapy occurred
most frequently. In patients starting on combination ther-
apy, a switch was the most common first change in therapy
and occurred in about one-third of the patients.
Table 1 General characteristics at baseline per type of initial OAD-therapy
Type of initial OAD-therapy
Metformin
(N = 14,277)
SU
(N = 18,876)
TZD
(N = 310)
Metformin ? SU
(N = 1,426)
Metformin ? TZD
(N = 73)
Other OADa
(N = 552)
n % n % n % n % n % n %
Gender
Male 6,709 47.0 9,426 49.9 157 50.6 747 52.4 40 54.8 260 47.1
Female 7,568 53.0 9,450 50.1 153 49.4 679 47.6 33 45.2 292 52.9
Age (years)
30–44 1,528 10.7 1,358 7.2 41 13.2 144 10.1 11 15.1 86 15.6
45–54 3,014 21.1 2,843 15.1 57 18.4 251 17.6 17 23.3 104 18.8
55–64 4,100 28.7 4,448 23.6 85 27.4 355 24.9 21 28.8 145 26.3
65–75 3,543 24.8 5,310 28.1 95 30.6 382 26.8 17 23.3 127 23.0
C76 2,092 14.7 4,917 26.0 32 10.3 294 20.6 7 9.6 90 16.3
Initial prescriber
General practitioner 12,572 88.1 16,006 84.8 209 67.4 1,060 74.3 54 74.0 325 58.9
Internist 1,148 8.0 1,729 9.2 87 28.1 210 14.7 16 21.9 148 26.8
Cardiologist 105 0.7 218 1.2 2 0.6 38 2.7 2 2.7 10 1.8
Specialist, other 452 3.2 923 4.9 12 3.9 118 8.3 1 1.4 69 12.5
HbA1c at baselined
n = 1.859 n = 1,963 n = 58 n = 167 b c
HbA1c \ 7% 501 26.9 429 21.9% 27 46.6 40 24.0% b b c c
HbA1c C 7% 1.358 73.1 1,534 78.1% 31 53.4 127 76.0% b b c c
OAD oral antidiabetic drug; SU sulphonylurea; TZD thiazolidinedionen
a Includes acarbose, glinidines, other combination therapies with OAD, and combination therapy of OADs and insulin
b The number of patients on initial metformin ? TZD combination therapy (n = 4) was too small, therefore these patients were excluded from
this HbA1c-analysis
c For patients who started on other types of OAD, HbA1c-values were not studied
d HbA1c levels were considered to be at baseline if they had been determined within a period up to 2 years prior to the cohort entry date
Table 2 First therapy change within one year after start, per type of initial OAD
Initial OAD-therapy All patients Patients with a change Add-on Switch Discontinue therapy
n n % na % na % na %
Metformin monotherapy 14,277 5,975 41.8 2,585 18.1 1,085 7.6 2,297 16.1
SU-monotherapy 18,876 7,605 40.3 2,895 15.3 913 4.8 3,791 20.1
TZD-monotherapy 310 167 53.8 63 20.3 25 8.1 78 25.2
Metformin ? SU combined 1,426 693 48.6 58 4.1 475 33.3 158 11.1
Metformin ? TZD combined 73 33 45.2 4 5.5 22 30.1 6 8.2
OAD oral antidiabetic drug; SU sulphonylurea; TZD thiazolidinedione
a Expressed as percentage of total per initial OAD-therapy; numbers do not add up to total patients with a change in each initial therapy group
because of 18 patients discontinuation could not be assessed
624 Pharm World Sci (2009) 31:622–626
123
Discussion
This study gives a descriptive overview of therapy with
OADs. The strength of this study is that pharmacy dis-
pensing records were linked to individual patients,
reflecting ‘real life’ OAD-therapy. This made it possible to
follow individual drugs over time. In general, OAD treat-
ment patterns observed in our study were in line with
international and national guidelines [5]. Overall, in about
41% of patients a change in OAD-therapy was observed in
the first year. This is in line with the rates of change
reported by others [6]. The proportion of patients on initial
therapy observed for metformin (58%) and SU (60%) were
also in agreement with literature [7]. The proportions of
patients on initial therapy were the lowest for the TZDs
(46%) and for combination therapies (53%). A possible
explanation might be that these patients were high-risk
patients, who were monitored more often and consequently
therapy was modified more often. Among patients starting
on monotherapy, observed therapy changes were in line
with the guidelines: if monotherapy failed, a combination
of metformin ? SU was used. Contrary to what might be
expected, we did not observe that patients starting on
combination therapy often changed all of these initial
OADs. Most of these patients switched to monotherapy of
one of the two initial OADs. A possible explanation might
be overdosing or necessity to increase one drug but not the
other. Another important observation is that the majority of
the patients had an HbA1c larger than 7% at start. How-
ever, 16–25% of the patients on initial OAD monotherapy
discontinued therapy without any switch. This might sug-
gest bad tolerance or poor adherence. Further research
might provide possible explanations for these observations.
Limitations
Obesity at initial diagnosis and treatment of T2DM as well
as, further, weight gain due to OADs are major problems in
T2DM management. Data on BMI, change of weight or use
of anti-obesity drugs were not available for this study.
Secondly, the distribution of type of initial OAD-therapy in
our study population, differed from current daily practice
as guidelines have changed [8]. Post-hoc analyses showed
that changing of guidelines was also observed in our study
population. Stratified by year of start of OAD-therapy, the
percentage of patients starting on SU decreased from 75%
in 1999 to 30% in 2004, while the percentage of patients
starting on metformin increased from 18% in 1999 to 62%
in 2004. Furthermore, characteristics of patients for dif-
ferent OAD-therapies were similar, except for the TZDs.
Furthermore, the number of patients on initial TZD therapy
was rather small. This might be explained by channeling
[9], that is selective prescribing of new drugs to specific
patients. Another important limitation is that for only 10%
of the cohort HbA1c data were available at baseline. In our
study period, HbA1c levels were measured once a year.
Therefore, we decided to include HbA1c values over the
longest possible period of time which was also still real-
istic, i.e. within a period of up to 2 years to cohort entry
date. There were no differences in general characteristics
between patients with and without HbA1c data, so patients
with HbA1c measurements were representative for the
entire cohort.
Conclusion
In daily practice in many patients a change in initial OAD-
therapy is observed in the first year of therapy, particularly
with initial TZD monotherapy. This suggests that this ini-
tial therapy was often unsatisfactory, either according to
the patient, the physician, or both. New users of OADs may
benefit from regular monitoring of effectiveness of pro-
portions of patients on initial therapy, allowing for patient-
tailored therapy, in case changes in therapy are indicated.
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